High-Dose Indium ¹¹¹in Pentetreotide Radiotherapy for Metastatic Atypical Carcinoid Tumor

Indium In 111 pentetreotide imaging of neuroendocrine tumors that overexpress somatostatin receptors has become standard for localization of these tumors. This radioligand is internalized into the cell and can induce receptor-specific cytotoxicity by emission of Auger electrons. We hypothesized that high-dose ¹¹¹In-pentetreotide could be therapeutic in patients with somatostatin receptor-expressing tumors. Our 35-year-old patient had atypical carcinoid tumor metastatic to cervical, supraclavicular, mediastinal, and mesenteric lymph nodes and to the liver and bone. Chemotherapy had stabilized the disease but with severe gastrointestinal side effects. After a diagnostic ¹¹¹In-pentetreotide scan, the patient was given eight courses (180 mCi each) of ¹¹¹In-pentetreotide therapy to selectively target somatostatin receptor-expressing tumor cells. The disease was stable for approximately 14 months. The patient had two additional courses of ¹¹¹In-pentetreotide therapy (360 mCi each). She died of the disease approximately 18 months after initiation of ¹¹¹In-pentetreotide therapy.